Dr. Reddy's Laboratories Ltd (RDY): Price and Financial Metrics


Dr. Reddy's Laboratories Ltd (RDY): $55.36

-0.03 (-0.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RDY POWR Grades


  • Stability is the dimension where RDY ranks best; there it ranks ahead of 89.42% of US stocks.
  • RDY's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • RDY ranks lowest in Momentum; there it ranks in the 8th percentile.

RDY Stock Summary

  • RDY's current price/earnings ratio is 2,975.43, which is higher than 99.74% of US stocks with positive earnings.
  • With a price/sales ratio of 270.7, Dr Reddys Laboratories Ltd has a higher such ratio than 98.77% of stocks in our set.
  • Revenue growth over the past 12 months for Dr Reddys Laboratories Ltd comes in at -98.4%, a number that bests only 0.78% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to RDY, based on their financial statements, market capitalization, and price volatility, are APPF, TARO, NXGN, FREE, and ICCC.
  • RDY's SEC filings can be seen here. And to visit Dr Reddys Laboratories Ltd's official web site, go to www.drreddys.com.

RDY Stock Price Chart Interactive Chart >

Price chart for RDY

RDY Price/Volume Stats

Current price $55.36 52-week high $75.50
Prev. close $55.39 52-week low $47.88
Day low $55.01 Volume 21,417
Day high $55.47 Avg. volume 193,158
50-day MA $53.85 Dividend yield 0.51%
200-day MA $58.47 Market Cap 9.21B

Dr. Reddy's Laboratories Ltd (RDY) Company Bio


Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.


RDY Latest News Stream


Event/Time News Detail
Loading, please wait...

RDY Latest Social Stream


Loading social stream, please wait...

View Full RDY Social Stream

Latest RDY News From Around the Web

Below are the latest news stories about Dr Reddys Laboratories Ltd that investors may wish to consider to help them evaluate RDY as an investment opportunity.

''Mankind Pharma'' To Acquire Two Brands From Dr Reddy''s Laboratories

Mankind Pharma on Wednesday said it has inked a pact with Dr Reddy''s Laboratories to acquire two brands -- Combihale and Daffy. While Combihale is used for the treatment of asthma and chronic obstructive pulmonary disease, Daffy is a soap-free moisturising

Goodreturns | February 16, 2022

Mankind Pharma to acquire 2 brands from DRL

Mankind Pharma on Wednesday said it has inked a pact with Dr Reddy''s Laboratories to acquire two brands -- Combihale and Daffy. While Combihale is used for the treatment of asthma and chronic obstructive pulmonary disease, Daffy is a soap-free moisturising bar for infants. Mankind Pharma said the market for Combihale is valued at Rs 900 crore growing at 14 per cent.

Economic Times India | February 16, 2022

Dr Reddy inks exclusive commercial agreements with Novartis for select brands

Dr Reddy''S Laboratories has entered into an exclusive sales and distribution agreement with Novartis India (NIL) for the Voveran range, the calcium range and Methergine in India.

Business Standard | February 13, 2022

Novartis India signs sales and distribution pact with Dr Reddy''s Laboratories; to lay off 400 employees

Novartis India has signed an exclusive sales and distribution pact with Dr Reddys Laboratories for a few of its medicines

CNBC TV18 | February 12, 2022

Dr Reddy''s inks exclusive sales pact with Novartis India

Dr Reddy''s Laboratories has entered into an exclusive sales and distribution agreement with Novartis India Ltd (NIL), a statement said on Friday. However, this will also lead to around 400 NIL employees being laid off due to role redundancies. Under the arrangement, Dr Reddy''s will have exclusive rights to promote and distribute the well-established Voveran range, the Calcium range and Methergine in India. The company will use its strengths in promotion and distribution to considerably expand its engagement with healthcare professionals with the aim of enabling access to patients in need. "We are delighted to enter into this arrangement with NIL to promote and distribute these well-established brands that are trusted by patients and healthcare professionals," Dr Reddy''s Laboratories ...

Economic Times India | February 11, 2022

Read More 'RDY' Stories Here

RDY Price Returns

1-mo 0.16%
3-mo -0.82%
6-mo -15.36%
1-year -25.76%
3-year 49.87%
5-year 36.10%
YTD -15.36%
2021 -7.49%
2020 76.61%
2019 8.38%
2018 1.18%
2017 -16.47%

RDY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full RDY Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5642 seconds.